Recent studies show that blockage of Siglec-1 on monocyte-derived dendritic cells (MDDCs) decreased SARS-CoV-2 viral transfer or trans-infection to bystander target cells (43), and Siglec1 was associated with disease severity (44) and enhanced SARS-CoV-2 infection and influenced neutralizing antibodies (45). Here, SIGLEC1 is linked to infection.